Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (581)	4/19/2000 7:54:00 AM
From: Jim Oravetz	Read Replies (2) \| Respond to of 1834

Neurocrine Biosciences Inc. (Nasdaq:NBIX) Wednesday announced results from a Phase I/II clinical trial in patients with advanced malignant glioma. Based on magnetic resonance imaging (MRI) findings reported by the investigators, 56% of patients exhibited a therapeutic response (greater than a fifty percent reduction in tumor size). No significant peripheral drug-related toxicity was observed. While approximately one third of the patients exhibited side effects during or immediately following therapy, they are consistent with marked tumor cell death and the subsequent inflammatory response resulting from the IL-4 toxin therapy. Based on these results, the company expects to initiate a Phase II clinical study to bridge into a pivotal Phase III efficacy trial. Thirty-one patients with end-stage (grade 4) recurrent glioblastoma, unresponsive to surgery and radiotherapy, were treated with intratumoral infusions of IL-4 for up to four days in a Phase I/II study conducted at nine leading neurosurgery centers in the USA and Germany. Treating physicians were asked to rate the patients' response to therapy at the last evaluable follow-up visit which ranged from 1-16 months. Twenty-nine of the 31 patients were available for evaluation. Four patients (13%) were reported as having complete remissions (no evidence of viable tumor); 14 patients (48%) experienced a partial response (greater than a 50% reduction in tumor mass). Seven patients (24%) were rated with stable disease, with the remaining four patients (13%) experiencing progressive disease. snip... Jim